DAX24.856 -0,5%Est506.036 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,7200 -0,6%Nas23.066 -0,2%Bitcoin56.692 +0,5%Euro1,1877 ±-0,0%Öl69,63 +0,8%Gold5.064 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Gerresheimer A0LD6E SAP 716460 Rheinmetall 703000 BASF BASF11 NVIDIA 918422 Deutsche Telekom 555750 Lufthansa 823212 Commerzbank CBK100 Microsoft 870747 Amazon 906866 Allianz 840400 DroneShield A2DMAA Bayer BAY001 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel in Rot -- US-Börsen kaum bewegt -- Deutsche Börse mit Rekordergebnis -- Siemens Energy: Rekordaufträge -- Lufthansa, Commerzbank, BMW, Telekom, Lyft, Moderna, Robinhood im Fokus
Top News
Ausblick: CANCOM SE legt Zahlen zum jüngsten Quartal vor Ausblick: CANCOM SE legt Zahlen zum jüngsten Quartal vor
Ausblick: Mercedes-Benz veröffentlicht Zahlen zum vergangenen Quartal Ausblick: Mercedes-Benz veröffentlicht Zahlen zum vergangenen Quartal
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

Genmab A-S Aktie

Kaufen
Verkaufen
Genmab A-S Aktien-Sparplan
252,50 EUR -6,40 EUR -2,47 %
BMN
252,40 EUR -7,20 EUR -2,77 %
GVIE
Genmab A-S jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.15,93 Mrd. EUR

KGV12,21Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN565131

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINDK0010272202

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolGNMSF

Genmab A-S Aktien News

DatumMeistgelesen
GlobeNewswireGenmab Publishes 2024 Annual Report
GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab
GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
GlobeNewswireGenmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireGenmab to Hold 2024 R&D Update and ASH Data Review Meeting
GlobeNewswireTwo Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
GlobeNewswireInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukem
GlobeNewswireInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswireTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
GlobeNewswireGenmab to Present at Citi’s Global Healthcare Conference
GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab
GlobeNewswireGenmab Announces Financial Results for the First Nine Months of 2024
GlobeNewswireGenmab to Present at Jefferies London Healthcare Conference
GlobeNewswireGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
GlobeNewswireMajor Shareholder Announcement
GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab
GlobeNewswireInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswireGenmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
GlobeNewswireTEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
GlobeNewswireGenmab Announces Changes to its Executive Committee
GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswireGenmab Announces Financial Results for the First Half of 2024
GlobeNewswireGenmab Updates 2024 Financial Guidance
GlobeNewswireGenmab Takes Full Control of Acasunlimab Development Program
GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
GlobeNewswireEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GlobeNewswireCompletion of Share Buy-back Program
GlobeNewswireEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GlobeNewswireTransactions in Connection with Share Buy-back Program
GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswireTransactions in Connection with Share Buy-back Program
GlobeNewswireGrant of Restricted Stock Units and Warrants to Employees in Genmab
GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GlobeNewswireTransactions in Connection with Share Buy-back Program
GlobeNewswireGenmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswireTransactions in Connection with Share Buy-back Program

Genmab A-S News

Genmab A-S News: auf dieser Seite finden Sie alle Genmab A-S News und Nachrichten zur Genmab A-S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Genmab A-S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Genmab A-S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.